Contact information
Research groups
Lisa Stockdale
MPH, PhD
Head of Pre-erythrocytic Malaria Vaccine Immunology
Pre-erythrocytic Malaria Clinical Trials
Senior Immunologist
Pre-erythrocytic Malaria Clinical Trials
As the Senior immunologist in the pre-erythrocytic malaria vaccine group, I coordinate the clinical immunology of all R21/Matrix-M vaccine trials. These include trials studying vaccine immunogenicity in populations with co-morbidities, different age groups, and using alternative dosing regimens.
Having spent 5 years in Industry working in small molecule drug development, I completed a Master of International Public Health at York University, and a PhD in Tuberculosis Vaccine Immunology at London School of Hygiene and Tropical Medicine, before joining the Oxford Vaccine Group as a post-doc where I conducted research on Typhoid conjugate vaccine immunology and Covid-19 vaccine development and immunology.
I joined the Pre-erythrocytic Malaria group at the Jenner Institute in 2021. My research interests include correlates of vaccine-induced protection, investigation of mediators of antibody function, immunological interactions between different pathogens and sero-epidemiology.
I am an Early Career Researcher representative for the Medical Sciences Division and the Nuffield Department of Medicine and a lead of the Jenner Research Staff Network.
Recent publications
Quantitative measures of human Cytomegalovirus infection and their associations with tuberculosis disease progression and Mycobacterium tuberculosis infection
Journal article
Stockdale L. et al, (2025), Philosophical Transactions of the Royal Society B: Biological Sciences, 380
Salmonella Typhi gut invasion drives hypoxic immune subsets associated with disease outcomes
Journal article
Bossel Ben-Moshe N. et al, (2025), Nature Communications, 16
R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial
Journal article
Kibwana E. et al, (2025), Frontiers in Immunology, 16
Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial
Journal article
Bundi C. et al, (2025), Frontiers in Immunology, 16
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18–45 years: an open-label, partially blinded, phase 1–2a controlled human malaria infection study
Journal article
Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100867 - 100867